师资队伍


扫描此二维码分享

当前位置: 首页 > 师资队伍 > 正文

周中振

发布时间:2019年10月19日 浏览次数:

姓名:周中振

职称:药物化学教授(广东省优秀青年教师

邮箱:zhouzz@smu.edu.cn

电话:020-61648594

大学以上学习经历

1. 2001/9~2007/7,华中师范大学农药与化学生物学教育部重点实验室,有机化学专业,博士研究生,理学博士学位,导师杨光富教授

2. 1997/9~2001/7,武汉化工学院制药系,本科,工学学士学位;

主要学术任职:

1. 中国抗炎免疫药理学会委员;

2. 广东省药学会药物化学专业委员会委员;

主要科研工作经历

1.2019//6 ~ 至今,南方医科大学,药学院,教授,博士研究生导师;

2.2019/1 ~ 2019/6,南方医科大学,药学院,副教授,博士研究生导师;

3.2016/6 ~ 2017/6,加拿大麦基尔大学,访问学者(导师:李朝军教授(皇家院士));

4.2011/12~2018/12,南方医科大学,药学院,副教授,硕士研究生导师;

5.2007/7~2011/11,南方医科大学,药学院,讲师;

获奖情况

1.2014年 广东省高等学校优秀青年教师培养计划培养对象;

2.2008年 广东省高等学校“千百十工程”第五批校级培养对象;

科研教学工作简介

周中振,博士,南方医科大学药学院药物化学专业教授, 博士生导师,广东省优秀青年教师,主要讲授课程为《有机化学》与《基础化学》,主要从事开展与神经系统相关疾病(如抑郁症、老年痴呆、帕金森病以及神经系统肿瘤)的新药物研究,先后主持多项国家自然科学基金,多项省自然科学基金与科技计划项目。至今已在Angew Chem. Int. Ed., ACS Catalysis, J. Med. Chem., Eur. J. Med. Chem., ACS Chem. Neurosci.等权威期刊发表SCI研究论文五十余篇,H-index为20。此外,授权专利6项,国际专利1项,成功转让专利一项。

主持或参加科研项目(课题)及人才计划项目情况(按时间倒序排序):

本人先后主持国家自然科学面上基金、广东省科技计划、广东省自然科学基金等多项基金。近几年科研项目如下:

1.2024-01-01至2026-12-31, 广东省自然科学基金项目,新型PDE7/4双靶点抗酒精成瘾与酒精肝损伤的药物发现,15万,在研,项目负责人。

2.2024-01-01至2027-12-31, 国家自然科学基金-联合基金项目(U23A20535), 靶向孕烷X受体促进肝脏再生的新机制与药物发现研究, 260万元, 在研, 参与(排名第二)。

3.2019.01至2022.12,国家自然科学面上基金(No. 81872735):靶向PDE4的新型抗抑郁药物的设计、合成与作用机制研究;55万,结题,项目负责人。

4.2018.05.01至2021.04.30,广东省自然科学基金项目(2018A030313046):靶向磷酸二酯酶IV的新型抑郁症药物的设计与合成;10万,结题,项目负责人。

5.2016.01至2018.12,广东省科技计划(No. 2016A020217008):具有改善认知作用的新型PDE4D抑制剂的设计、合成及生物活性研究;30万,结题,项目负责人。

6.2015.1至2017.30,广东省高等学校优秀青年教师培养计划2014年度培养对象(粤教师函〔2014〕145号),靶向微管蛋白的新型肿瘤血管阻断剂的设计与合成,30万,完成,项目负责人。

代表性研究成果(每项均按时间倒序排序)

[1] Zheng Lei, Aimaiti Zulihuma, Long Lu, Xia Chuang, Wang Wenya*, Zhou Zhong-Zhen*, Discovery of 4-Ethoxy-6-chloro-5-azaindazoles as Novel PDE4 Inhibitors for the Treatment of Alcohol Use Disorder and Alcoholic Liver Diseases, Journal of Medicinal Chemistry, 2024, 67: 728-753. (药物化学Top期刊,IF = 7.3I)

[2] Xia Chuang, He Jia-Peng, Feng Kai-Wen, Liu Lu, Zheng Lei , Wang Hai-Tao, Xu Jiang-Ping, Zhou, Zhong-Zhen*, Discovery of Novel 3-Amino-4-alkoxyphenylketones as PDE4 Inhibitors with Improved Oral Bioavailability and Safety against Spatial Memory Impairments, ACS Chemical Neuroscience, 2022, 13: 390-405. (SCI, IF = 4.418)

[3] Huang Liangfeng, Zheng Lei, Zhou Zhongzhen*, Chen Yunfeng*, Copper-catalyzed multiple oxidation and cycloaddition of aryl-alkyl ketones (alcohols) for the synthesis of 4-acyl- and 4-diketo-1,2,3-triazoles, Chem Commun (Camb), 2022, 58(20): 3342-3345 (SCI, IF = 6.222)

[4] Liu, Jie; Ye, Wan; Xu, Jiang-Ping; Wang, Hai-Tao; Li, Xiao-Fang; Wang, Wen-Ya*; Zhou, Zhong-Zhen*. "Discovery of novel trimethoxyphenyl- benzo[d]oxazoles as dual tubulin/PDE4 inhibitors capable of inducing apoptosis at G2/M phase arrest in glioma and lung cancer cells." European Journal of Medicinal Chemistry, 2021, 224: 113700 (SCI, IF = 6.514, I)

[5] He, JiaPeng; Zhang, Mao; Tang, Lv; liu, Jie; Zhong, JiaHong; Wang, Wenya; Xu, Jiang-Ping; Wang, Hai-Tao; Li, Xiao-Fang; Zhou Zhong-Zhen*. Synthesis, Biological Evaluation and Molecular Docking of Arylpyridines as Anti-proliferative Agent Targeting Tubulin. ACS Medicinal Chemistry Letters, 2020, 11(8), 1611–1619. (SCI, IF = 4.345, II)

[6] Tang, Lv; Huang, Chang; Zhong, Jiahong; He, JiaPeng; Guo, Jiayin; Liu, Menghua; Xu, Jiang-Ping*; Wang, Hai-Tao; Zhou Zhong-Zhen*. Discovery of arylbenzylamines as PDE4 inhibitors with potential neuroprotective effect. European Journal of Medicinal Chemistry, 2019, 168, 221-231. (SCI, IF = 6.514, I).

[7] Yang, Danni; Huang, Cuihong; Liao, Hui; Zhang, Huiwu; Wu, Shaoyu*; Zhu, Qiuhua*; Zhou, Zhong-Zhen*. Discovery of Dihydropyrrol-2-ones as Novel G0/G1-Phase Arresting Agents Inducing Apoptosis. ACS Omega, 2019, 4 17556-17560. (SCI, IF = 2.87)

[8] Zhou ZhongZhen; Liu, Mingxin; Lv, Leiyang; Li, Chao-Jun. Silver(I)-Catalyzed Widely Applicable Aerobic 1,2-Diol Oxidative Cleavage. Angewandte Chemie International Edition, 2018, 57 (10), 2616-2620. (SCI, IF = 15.336, ITop期刊).

[9] Zhou ZhongZhen; Liu, Mingxin; Li, Chao-Jun. Selective Copper–N-Heterocyclic Carbene (Copper-NHC)-Catalyzed Aerobic Cleavage of β-1 Lignin Models to Aldehydes. ACS Catalysis, 2017, 7 (5), 3344-3348. (SCI, IF = 13.084, ITop期刊).

[10] Zhou Zhong-Zhen*; Shi, Xiu-Dong; Feng, Hong-Fang; Cheng, Yu-Fang; Wang, Hai-Tao; Xu, Jiang-Ping*. Discovery of 9H-purins as potential tubulin polymerization inhibitors: Synthesis, biological evaluation and structure−activity relationships. European Journal of Medicinal Chemistry, 2017, 138, 1126-1134. (SCI, IF = 6.514, I).

[11] Zhou Zhong-Zhen*; Cheng, Yu-Fang; Zou, Zheng-Qiang; Ge, Bing-Chen; Yu, Hui; Huang, Cang; Wang, Hai-Tao; Yang, Xue-Mei*; Xu, Jiang -Ping*. Discovery of N-Alkyl catecholamides as selective phosphodiesterase-4 Inhibitors with anti-neuroinflammation potential Exhibiting antidepressant-like effects at non-emetic Doses. ACS Chemical Neuroscience, 2017, 8 (1), 135-146. (SCI, IF = 4.486, II).

[12] Ge, Bing-Chen; Feng, Hong-Fang; Cheng, Yu-Fang; Wang, Hai-Tao; Xi, Bao-Ming; Yang, Xue-Mei; Xu, Jiang-Ping*; Zhou Zhong-Zhen*. Design, synthesis and biological evaluation of substituted aminopyridazin-3(2H)-ones as G0/G1-phase arresting agents with apoptosis-inducing activities. European Journal of Medicinal Chemistry, 2017, 141 , 440-445. (SCI, IF = 6.514, I).

[13] Huang, Chang; Zhong, Qiu-Ping; Tang, Lv; Wang, Hai-Tao; Xu, Jiang-Ping*; Zhou Zhong-Zhen*. Discovery of 2-(3,4-dialkoxyphenyl)-2-(substituted pyridazin-3-yl)acetonitriles as phosphodiesterase 4 inhibitors with anti-neuroinflammation potential based on three-dimensional quantitative structure-activity relationship study. Chemical Biology & Drug Design 2019, 93 (4), 484-502. (SCI, IF = 2.817)

[14] Liu, Yi; Nie, Gang; Zhou Zhong-Zhen*; Jia, Lihui; Chen, Yunfeng*. Copper-Catalyzed Oxidative Cross-Dehydrogenative Coupling/Oxidative Cycloaddition: Synthesis of 4-Acyl-1,2,3-Triazoles. The Journal of Organic Chemistry, 2017, 82 (17), 9198-9203. (SCI, IF = 4.80, IITop期刊).

[15] Zhou Zhong-Zhen*; Ge, Bing-Chen; Zhong, Qiu-Ping; Huang, Chang; Cheng, Yu-Fang; Yang, Xue-Mei; Wang, Hai-Tao; Xu, Jiang-Ping*. Development of highly potent phosphodiesterase 4 inhibitors with anti-neuroinflammation potential: Design, synthesis, and structure-activity relationship study of catecholamides bearing aromatic rings. European Journal of Medicinal Chemistry, 2016, 124, 372-379. (SCI, IF = 6.514, I).

近年其它重要成果

授权发明专利

1.周中振; 何家朋; 刘洁; 胺基苯基酮类化合物及其制备方法与应用, 中国专利,专利号:202011057788.1。(已转让)

2.周中振,徐江平,黄昌,汪海涛. 3-芳基-4-烷氧基苄胺类衍生物的合成及其应用,中国专利,专利号:ZL 201810964371.X。

3.周中振,徐江平,黄昌,汪海涛. 3-芳基-4-烷氧基苄醚类衍生物的合成及其应用, 中国专利,专利号:ZL 201810964506.2。

5.徐江平,周中振,一种能避免呕吐反应的磷酸二酯酶4抑制剂,2014.2.12-2034.2.11,中国,ZL 201210037980.3。

6.周春琼,周中振,一种对称的多胺与吡咯聚酰胺缀合物及其制备方法。2011.09.14-2031.09.13,中国,ZL 20091019414.6

7.周中振,汤侣,徐江平. 一种1-芳基-3-(6-芳基吡啶-2-基)-丙烯酮及其制备方法与应用,中国专利,专利申请号:ZL 201910633037.0。

上一条:伍小云

下一条:赵鹏